Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Abroad (travel likely)RecruitingPHASE2

Conditions

Upper Urinary Tract Urothelial Carcinoma · Kidney Preservation · HER-2 ADC · PD-1antibody

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Qi Lu) · rjllb3364@163.com · +86021-68383364

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

Upper Urinary Tract Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Beijing, China

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Renal Insufficiency · Upper Urinary Tract Urothelial Carcinoma · Solitary Kidney

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

Urothelial Carcinoma · Cancer

Abroad (travel likely)RecruitingPHASE2

Paris, France · Marseille, France